Treats insomnia characterized. ANDA 72369, held by Chartwell Rx. Flurazepam Hydrochloride.
As of Nov 16, 2026, ANDA 72369 (Flurazepam Hydrochloride), held by Chartwell Rx, was first approved by FDA on Mar 30, 1989, with 7 approved supplements and 0 published complete response letters.
Flurazepam hydrochloride capsules are indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. Since insomnia is often transient and intermittent, short-term use is usually sufficient. Prolonged use of hypnotics is usually not indicated and should only be undertaken concomitantly with appropriate evaluation of the patient.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 30, 1989 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Flurazepam Hydrochloride30MG · capsule;oral | Flurazepam Hydrochloride | Rx |
| Jan 17, 2023 | Supplement 8Labeling · Standard review | Approved | None posted |
| Feb 8, 2021 | Supplement 7Labeling · Standard review | Approved | None posted |
| Dec 16, 2016 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jul 17, 1998 | Supplement 4Manufacturing | Approved | None posted |
| May 23, 1997 | Supplement 3Manufacturing | Approved | None posted |
| Jun 23, 1993 | Supplement 2Labeling | Approved | None posted |
| May 9, 1989 | Supplement 1Labeling | Approved | None posted |
| Mar 30, 1989 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters